Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 15/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 14/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 14/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21881665 | 0.96 | GNAO1 (0.39) | GNAO1GNAI3GNAI1CHRM1EPHX1 | |
| SCHEMBL21579334 | 0.94 | GNAO1 (0.40) | GNAO1GNAI3GNAI1CHRM1EPHX1 | |
| SCHEMBL19966917 | 0.93 | GNAO1 (0.42) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL21880962 | 0.78 | CNR1 (0.31) | — | |
| SCHEMBL21881668 | 0.75 | GNAO1 (0.40) | GNAO1GNAI3GNAI1CHRM1 | |
| SCHEMBL19230311 | 0.74 | ALDH1A1 (0.33) | — | |
| SCHEMBL21166176 | 0.73 | PDE4A (0.31) | — | |
| SCHEMBL76964 | 0.72 | HRH1 (0.35) | — | |
| SCHEMBL21880995 | 0.72 | GNAI3 (0.37) | GNAO1GNAI3GNAI1CHRM1 | |
| SCHEMBL22109249 | 0.70 | PDE4D (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-20 | — | — | US | disclosed |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | GNAO1 366/4885GNAI3 505/4885GNAI1 459/4885 |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | AR, SHBG, NR5A1 | GNAO1 366/4885GNAI3 505/4885GNAI1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.